Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man

Onkologie

Volumn 30, Issue 5, 2007, Pages 253-255

  Tavil, Yusuf ^a,b   Arslan, Uǧur ^a   Okyay, Kaan ^a   Şen, Nihat ^a   Boyaci, Bülent ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Atrial fibrillation; Chemotherapy; Gemcitabine

Indexed keywords

CISPLATIN; GEMCITABINE; PROPAFENONE; VERAPAMIL;

AGED; ANAMNESIS; ARTICLE; BRADYCARDIA; CANCER CHEMOTHERAPY; CARDIOVERSION; CASE REPORT; CLINICAL FEATURE; DIZZINESS; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPOTENSION; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALE; PHYSICAL EXAMINATION; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATRIAL FIBRILLATION; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RISK FACTORS;

EID: 34247553342     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100930     Document Type: Article

References (14)

1. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 1993;11:1391-402.
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
3. Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anticancer Drugs 1995;6:27-32.
4. Green MR: Gemcitabine safety overview. Semin Oncol 1996;23:32-5.
5. Storniolo AM, Allerheiligen SR, Pearce HL: Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24:2-7.
6. Santini D, Tonini G, Abbate A, Di Cosimo S, Gravante G, Vincenzi B, Campisi C, Patti G, Di Sciascio G: Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol 2000;11:479-81.
7. Ciotti R, Belotti G, Facchi E, Cantu A, D'Amico A, Gatti C: Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999;10:997.
8. Illiano A, Barletta E, De Marino V, Battiloro C, Barzelloni M, Scognamiglio F, Rossi N, Zampa G, De Bellis M, Gridelli C: New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res 2000;20:3999-4003.
9. Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, Ferrau F,Robbiati SF, Adamo V, Gasparini G, Novello S, Perrone F; MILES Investigators: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer;2001;31:277-84.
10. Ferrari D, Carbone C, Codeca C, Fumagalli L, Gilardi L, Marussi D, Tartaro T, Oldani S, Zannier F, Foa P: Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs 2006;17:359-61.
11. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
12. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ: Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37:371-8.
13. Van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH: Drug-induced atrial fibrillation. J Am Coll Cardiol 2004;44:2117-24.
14. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.